Your browser is no longer supported. Please, upgrade your browser.
AGEN Agenus Inc. daily Stock Chart
Agenus Inc.
Index- P/E- EPS (ttm)-1.23 Insider Own10.30% Shs Outstand145.06M Perf Week5.41%
Market Cap580.44M Forward P/E- EPS next Y-1.05 Insider Trans-4.20% Shs Float139.27M Perf Month-15.78%
Income-171.00M PEG- EPS next Q-0.27 Inst Own46.60% Short Float15.04% Perf Quarter30.31%
Sales85.30M P/S6.80 EPS this Y44.60% Inst Trans0.49% Short Ratio6.56 Perf Half Y-6.76%
Book/sh-1.35 P/B- EPS next Y0.00% ROA-95.40% Target Price- Perf Year51.14%
Cash/sh0.53 P/C6.29 EPS next 5Y- ROE87.90% 52W Range1.82 - 4.78 Perf YTD-18.67%
Dividend- P/FCF- EPS past 5Y-2.30% ROI- 52W High-30.83% Beta1.96
Dividend %- Quick Ratio- Sales past 5Y84.70% Gross Margin- 52W Low81.87% ATR0.20
Employees328 Current Ratio0.80 Sales Q/Q-81.10% Oper. Margin- RSI (14)44.73 Volatility6.30% 6.17%
OptionableYes Debt/Eq- EPS Q/Q-348.30% Profit Margin- Rel Volume0.57 Prev Close3.34
ShortableYes LT Debt/Eq- EarningsAug 06 BMO Payout- Avg Volume3.19M Price3.31
Recom1.30 SMA20-3.52% SMA50-9.62% SMA2000.10% Volume1,815,957 Change-0.90%
Nov-19-19Resumed B. Riley FBR Buy $6
Apr-22-19Initiated B. Riley FBR Buy
Oct-28-16Downgrade H.C. Wainwright Buy → Neutral $10 → $5
Oct-27-16Reiterated Maxim Group Buy
Mar-11-16Upgrade Maxim Group Hold → Buy $7
Dec-16-15Initiated Jefferies Buy
Oct-27-15Downgrade Maxim Group Buy → Hold
Jul-27-15Reiterated MLV & Co Buy $9 → $11
Jun-11-15Initiated Oppenheimer Outperform $14
Jan-12-15Reiterated Maxim Group Buy $10 → $11
Jan-09-15Reiterated MLV & Co Buy $6 → $9
Jan-09-15Reiterated Maxim Group Buy $10 → $11
Dec-19-14Reiterated Maxim Group Buy $8 → $10
May-08-14Reiterated Maxim Group Buy $17 → $11
Mar-14-14Reiterated MLV & Co Buy $9 → $11
Oct-08-13Reiterated Maxim Group Buy $19
Jan-05-12Initiated William Blair Outperform
Dec-01-11Initiated Global Hunter Securities Buy $6
Aug-06-20 11:55AM  
Aug-05-20 12:00PM  
Jul-21-20 01:31PM  
Jul-13-20 12:00PM  
Jul-05-20 03:40PM  
Jul-03-20 10:25AM  
Jun-26-20 12:00PM  
Jun-25-20 11:30AM  
Jun-24-20 04:53PM  
Jun-23-20 10:34AM  
Jun-22-20 09:43AM  
Jun-17-20 11:06AM  
Jun-16-20 08:12AM  
Jun-08-20 02:32PM  
Jun-06-20 11:31AM  
Jun-05-20 12:37AM  
Jun-03-20 07:39AM  
Jun-02-20 11:30AM  
Jun-01-20 09:21AM  
May-29-20 01:28PM  
May-28-20 09:42AM  
May-26-20 05:47PM  
May-14-20 11:56AM  
May-13-20 09:54AM  
May-11-20 12:00PM  
May-08-20 07:30PM  
May-07-20 09:35AM  
Apr-30-20 12:34PM  
Apr-28-20 11:50AM  
Apr-16-20 08:56AM  
Apr-07-20 01:04PM  
Apr-06-20 09:00AM  
Mar-24-20 12:00PM  
Mar-16-20 06:09AM  
Mar-13-20 11:57AM  
Mar-12-20 10:05AM  
Mar-10-20 09:14AM  
Mar-05-20 12:30PM  
Mar-03-20 08:00AM  
Feb-28-20 08:58AM  
Feb-27-20 09:10AM  
Feb-21-20 12:00PM  
Feb-20-20 09:56AM  
Feb-06-20 03:12PM  
Jan-17-20 05:12AM  
Jan-09-20 10:59AM  
Jan-08-20 10:04AM  
Jan-03-20 10:54AM  
Dec-19-19 10:37PM  
Dec-16-19 12:00PM  
Dec-05-19 09:42PM  
Dec-04-19 11:30AM  
Nov-20-19 09:39AM  
Nov-18-19 09:50AM  
Nov-13-19 09:05AM  
Nov-12-19 12:48PM  
Nov-11-19 08:00AM  
Nov-08-19 08:14AM  
Nov-07-19 10:00AM  
Nov-06-19 01:53PM  
Nov-05-19 11:09AM  
Nov-04-19 08:25AM  
Oct-31-19 12:04PM  
Oct-29-19 10:32AM  
Oct-19-19 08:26AM  
Sep-30-19 04:34PM  
Sep-07-19 09:30AM  
Sep-04-19 11:52AM  
Aug-15-19 06:51PM  
Aug-10-19 01:43AM  
Aug-09-19 11:09AM  
Agenus Inc., a clinical-stage immuno-oncology company, engages in advancing a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; and display technologies. In addition, the company develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neoantigen; PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neoepitopes; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Further, it develops CTLA-4 and PD-1 antagonists which is in clinical trial phase I for the dose escalation study; AGEN2373, an anti-CD137 monospecific antibody which is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody designed to deplete regulatory T cells which is in a Phase 1 clinical trial; GS-1423, a tumor microenvironment conditioning anti-CD73/TGF TRAP bifunctional antibody which is in Phase 1 clinical trial; and TIGIT antibodies. Additionally, the company engages in the development INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390 A an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
INCYTE CORP10% OwnerJun 17Sale3.66141,920518,83116,972,968Jun 18 05:30 PM
INCYTE CORP10% OwnerJun 16Sale3.6672,080264,00717,114,888Jun 18 05:30 PM
INCYTE CORP10% OwnerJun 15Sale3.57384,0251,372,16017,186,968Jun 15 08:47 PM
INCYTE CORP10% OwnerJun 12Sale3.589,10032,55617,570,993Jun 15 08:47 PM
INCYTE CORP10% OwnerJun 11Sale3.77183,875692,78617,580,093Jun 15 08:47 PM